Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Release of dengue virus genome induced by a peptide inhibitor.

Lok SM, Costin JM, Hrobowski YM, Hoffmann AR, Rowe DK, Kukkaro P, Holdaway H, Chipman P, Fontaine KA, Holbrook MR, Garry RF, Kostyuchenko V, Wimley WC, Isern S, Rossmann MG, Michael SF.

PLoS One. 2012;7(11):e50995. doi: 10.1371/journal.pone.0050995. Epub 2012 Nov 30.

2.

Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.

Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, Bazzone LE, Hogancamp G, Figueroa Sierra M, Fong RH, Yang ST, Lin L, Robinson JE, Doranz BJ, Chernomordik LV, Michael SF, Schieffelin JS, Isern S.

J Virol. 2013 Jan;87(1):52-66. doi: 10.1128/JVI.02273-12. Epub 2012 Oct 17.

3.

Viral entry inhibitors block dengue antibody-dependent enhancement in vitro.

Nicholson CO, Costin JM, Rowe DK, Lin L, Jenwitheesuk E, Samudrala R, Isern S, Michael SF.

Antiviral Res. 2011 Jan;89(1):71-4. doi: 10.1016/j.antiviral.2010.11.008. Epub 2010 Nov 18.

PMID:
21093488
4.

Structural optimization and de novo design of dengue virus entry inhibitory peptides.

Costin JM, Jenwitheesuk E, Lok SM, Hunsperger E, Conrads KA, Fontaine KA, Rees CR, Rossmann MG, Isern S, Samudrala R, Michael SF.

PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721. doi: 10.1371/journal.pntd.0000721.

5.

Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient.

Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, Isern S, Michael SF, Robinson JE.

Virol J. 2010 Feb 4;7:28. doi: 10.1186/1743-422X-7-28.

6.

In vitro inhibition of dengue virus entry by p-sulfoxy-cinnamic acid and structurally related combinatorial chemistries.

Rees CR, Costin JM, Fink RC, McMichael M, Fontaine KA, Isern S, Michael SF.

Antiviral Res. 2008 Nov;80(2):135-42. doi: 10.1016/j.antiviral.2008.05.007. Epub 2008 Jun 13.

PMID:
18606464
7.

Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein.

Costin JM, Rausch JM, Garry RF, Wimley WC.

Virol J. 2007 Nov 20;4:123.

8.

Cytopathic mechanisms of HIV-1.

Costin JM.

Virol J. 2007 Oct 18;4:100. Review.

9.

Human, rhesus macaque, and feline sequences highly similar to mouse mammary tumor virus sequences.

Szabo S, Haislip AM, Traina-Dorge V, Costin JM, Crawford BE 2nd, Wilson RB, Garry RF.

Microsc Res Tech. 2005 Nov;68(3-4):209-21.

PMID:
16276510
10.

Concentration-dependent differential induction of necrosis or apoptosis by HIV-1 lytic peptide 1.

Plymale DR, Comardelle AM, Fermi CD, Martin DS, Costin JM, Norris CH, Tencza SB, Mietzner TA, Montelaro RC, Garry RF.

Peptides. 1999 Nov;20(11):1275-83.

PMID:
10612441

Supplemental Content

Loading ...
Support Center